User shares one-year hair transplant results with 3633 FUE grafts. Responses discuss improved appearance, hairline looking pluggy, and doctor's location in Ottawa, Canada.
A 24-year-old experienced significant hair regrowth over a year using 1mg finasteride daily and 2.5mg oral minoxidil. The results appear natural without enhancements.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.
Scalp micropigmentation as a treatment for hair loss, and the importance of choosing a reputable practitioner to get a natural look. Different treatments such as laser removal were also discussed in relation to long-term maintenance.
The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.
A 21-year-old male has used 5% topical minoxidil and 1.25mg finasteride for 2 years, improving overall hair but not regrowing temples or crown. He is considering additional treatments like microneedling or dutasteride after a clinic advised against a hair transplant due to existing but damaged follicles.
Hair loss treatments discussed include minoxidil, finasteride, dutasteride RU, derma rolling, pyrilutamide, cosmeRNA, hair systems, and essential oils. The user seeks information on additional treatments, safety profiles, and alternative options for androgenetic alopecia.
Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.
The user shared positive hair regrowth results using Minoxidil 5% and stinging nettle root over six months. They avoided finasteride due to concerns but are open to using it if needed.
A user, 35M, has been using oral finasteride for 5 years and 5% minoxidil for 3 years, which stopped hair loss but didn't promote regrowth. After starting RU58841 5 months ago, they noticed long, translucent hairs and are asking if these hairs will darken and how to encourage this.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.
The user shared positive results from using Minoxidil twice daily, Finasteride 1mg, and microneedling for hair loss, noting improved hair density and mental health. They emphasized the importance of consistency and patience, mentioning initial shedding phases but no significant side effects.
A user regrew all their hair, including temples and bald spots, after one year of finasteride and six months of oral minoxidil. They noted finasteride helped with the crown and bald spot, while minoxidil regrew the hairline and temples.
The user applied minoxidil and finasteride topically for hair regrowth, experiencing significant results but stopped finasteride due to side effects. They later added stevia to minoxidil, noticing potential improvement in hair density, particularly at the front.
The user reported significant hair regrowth after seven months using topical minoxidil 5% combined with 0.1% finasteride and weekly micro needling. The community responded positively, noting visible improvement and discussing the effectiveness of topical versus oral finasteride.
The user experienced significant hair regrowth after 11 months on 1mg finasteride, despite minoxidil only providing temporary results. The conversation includes questions about the use of minoxidil and other treatments, with users noting improvements in hair density and temple peaks.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
A 40+ male shared his one-year progress using minoxidil twice daily and microneedling once a week, showing significant hair improvement. He also occasionally uses finasteride in a low dosage due to side effects.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
Significant hair regrowth was achieved using a topical combination of 0.3% finasteride and 6% minoxidil, with weekly dermastamping and ketoconazole shampoo, without side effects. Others suggested additional treatments like red light therapy and PRP.
A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.
A 21-year-old male shares his 3-month progress using 0.5mg dutasteride daily, 5% topical minoxidil twice daily, and weekly microneedling, showing some temple recovery and seeking further improvement. Feedback suggests continued use and monitoring, with optimism for more regrowth over time.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
The conversation is about potential causes of hair loss and treatments, including topical and oral minoxidil, finasteride, and dutasteride, with a focus on checking for vitamin deficiencies and conditions like Lichen Planopolaris. It also discusses the skepticism around certain tests and the success of hair transplants.
A 43-year-old male saw significant hair regrowth and increased density after three months using topical Minoxidil (5%), topical Finasteride (0.025%), and 0.75mm microneedling every two weeks, with no side effects. He plans to continue and may reduce Finasteride concentration if progress continues.